Heidelberg Pharma Received Development Milestone Payment from Partner Takeda
Ladenburg, Germany, 29 January 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it has received a milestone payment under the terms of its license agreement with partner Takeda based on the achievement of a clinical development milestone for Takeda’s investigational medicine that utilizes Amanitin-based Antibody Drug Conjugate (ATAC) technology licensed from Heidelberg Pharma. With the dosing of the first patient in a Phase I/II clinical trial in patients with solid tumors, a milestone payment to Heidelberg Pharma became due. Financial details were not disclosed.
Dr. Dongzhou Jeffery Liu, Chief Executive Officer of Heidelberg Pharma AG, commented: “We are very delighted that our partner Takeda is progressing the development of their investigational medicine that utilizes ATAC technology, and that we have received the according milestone payment. We congratulate the Takeda team and wish them every success in clinical development. With this, three candidates that leverage ATAC technology are now in clinical development, two that are proprietary to Heidelberg Pharma including HDP-101 (INN: pamlectabart tismanitin) and HDP-102, and one under the responsibility of our partner. For us, this is a further validation of the potential of our unique Amanitin-based ADC technology.”
Takeda exclusively licensed the worldwide development and commercialization rights from Heidelberg Pharma for the use of the ATAC technology with an antibody directed to a defined target and the resulting product candidate. Under the terms of the agreement, Takeda is responsible for the development, as well as commercialization, of the resulting product candidate.
